SCHEMBL84539

SCHEMBL84539

Cc1n[nH]c2ccc(C(C)(C)C)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.47
FGFR1 P11362 2/20 0.44
FLT3 P36888 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
JAK2 O60674 2/20 0.43
PLK4 O00444 1/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
CHUK O15111 1/20 0.43
PDPK1 O15530 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
CHEK2 O96017 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43
PRKCG P05129 1/20 0.43
INSR P06213 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22339348 0.86 JAK2 (0.51) KIF11JAK2PDPK1GSK3BJAK3
SCHEMBL12962020 0.85 KIF11 (0.47) KIF11FGFR1FLT3CLK4JAK2
SCHEMBL13122324 0.84 MAP2K4 (0.56) KIF11CHUKGSK3BADORA2AADORA2B
SCHEMBL13893771 0.83 ADORA2A (0.39) FGFR1FLT3CLK4JAK2PLK4
SCHEMBL1690470 0.81 JAK2 (0.55) KIF11CLK4JAK2PLK4CHEK1
SCHEMBL21018486 0.81 KIF11 (0.47) KIF11FGFR1FLT3CLK4JAK2
SCHEMBL1691723 0.80 KIF11 (0.46) KIF11FGFR1FLT3CLK4JAK2
SCHEMBL14827609 0.80 KIF11 (0.46) KIF11FGFR1FLT3CLK4JAK2
SCHEMBL20085919 0.80 KIF11 (0.46) KIF11FGFR1FLT3CLK4JAK2
SCHEMBL2054573 0.77 KIF11 (0.44) KIF11FGFR1FLT3CLK4JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-02-29 US disclosed
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-02-29 US disclosed
EP-4233859-A1 INHIBITORS OF KINASE NETWORKS AND USES THEREOF Purdue Research Foundation (US) 2023-08-30 EP disclosed
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-11731967-B2 Inhibitors of TRIM33 and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-08-22 US disclosed
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2023-02-02 US disclosed
US-20220389021-A1 INHIBITORS OF KRAS G12C BEONE MEDICINES I GMBH (CH) 2022-12-08 US disclosed
US-20220378743-A1 METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2022-12-01 US disclosed
EP-3421465-B1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF BEIJING TIDE PHARMACEUTICAL CO LTD (CN) 2022-10-26 EP disclosed
US-20210371420-A1 INHIBITORS OF KINASE NETWORKS AND USES THEREOF PURDUE RESEARCH FOUNDATION 2021-12-02 US disclosed
US-20090275592-A1 Heterocyclic modulators of PKB AMGEN INC. (US) 2009-11-05 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
US-7393848-B2 Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds CGI PHARMACEUTICALS, INC. (US) 2008-07-01 US disclosed
US-20080125417-A1 CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. 2008-05-29 US disclosed
US-20080064703-A1 Fused bicycloheterocycle substituted quinuclidine derivatives ABBVIE INC. 2008-03-13 US disclosed
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use AMGEN INC. 2007-08-09 US disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed
US-20070060588-A1 Fused bicycloheterocycle substituted quinuclidine derivatives ABBOTT LABORATORIES 2007-03-15 US disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731967-B2 Inhibitors of TRIM33 and methods of use TRIM33, TRIM28, TRIM4 KIF11 2061/4885FGFR1 4724/4885FLT3 1822/4885
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use BRAF, NRAS, RAF1 KIF11 3671/4885FGFR1 491/4885FLT3 207/4885
US-20070060588-A1 Fused bicycloheterocycle substituted quinuclidine derivatives CHRNA1, CHRNA7, CHRNA2 KIF11 3548/4885FGFR1 2944/4885FLT3 3281/4885
US-20090275592-A1 Heterocyclic modulators of PKB MTOR, PDK1, EIF4EBP1 KIF11 4832/4885FGFR1 986/4885FLT3 1602/4885
US-20080064703-A1 Fused bicycloheterocycle substituted quinuclidine derivatives IDO1, IDO2, HTR3C KIF11 1020/4885FGFR1 1045/4885FLT3 1087/4885
US-20210371420-A1 INHIBITORS OF KINASE NETWORKS AND USES THEREOF KDM1B, JMJD6, KDM1A KIF11 2865/4885FGFR1 1655/4885FLT3 556/4885
US-20230030115-A1 RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF ROCK1, ROCK2, RHOA KIF11 800/4885FGFR1 2248/4885FLT3 2613/4885
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 KIF11 2865/4885FGFR1 318/4885FLT3 556/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 KIF11 3937/4885FGFR1 123/4885FLT3 753/4885
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE TRIM33, TRIM28, TRIM4 KIF11 2061/4885FGFR1 4724/4885FLT3 1822/4885
US-20080125417-A1 CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, TK1 KIF11 4282/4885FGFR1 1463/4885FLT3 31/4885
US-20220389021-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KIF11 1797/4885FGFR1 2243/4885FLT3 1370/4885
US-20220378743-A1 METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS SLC10A1, CYP7A1, FABP1 KIF11 3237/4885FGFR1 483/4885FLT3 3248/4885
US-20070054903-A1 Bis-aryl kinase inhibitors and method HGF, MET, BLK KIF11 3517/4885FGFR1 8/4885FLT3 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.